Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
This is a safety and tolerability study looking at the addition of avelumab, an immune checkpoint inhibitor, to standard therapy of temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme.
All patients will be receiving active therapy. Patients will begin the avelumab within 3 weeks of finishing their radiotherapy. Avelumab will be given at a dose of 10mg/kg IV every 2 weeks concomitantly with the monthly temozolomide. Avelumab will be continued for a total of 52 weeks.
Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting
Study Objectives and Endpoints:
Objective:
The primary objective of the study is to evaluate the feasibility and test-retest reliability of MEP's and (SSEP's) in a multicenter clinical trial in healthy subjects and subjects with MS.
Endpoints:
The primary reliability endpoint will be the intraclass correlation coefficient (ICC) of the following evoked potential parameters
100 项与 Clinique Neuro-Outaouais 相关的临床结果
0 项与 Clinique Neuro-Outaouais 相关的专利(医药)
100 项与 Clinique Neuro-Outaouais 相关的药物交易
100 项与 Clinique Neuro-Outaouais 相关的转化医学